NCT06993844 2026-03-17
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Phase 1/2 Recruiting
Ensem Therapeutics
Atavistik Bio, Inc
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Eli Lilly and Company
AstraZeneca
Carrick Therapeutics Limited
Boehringer Ingelheim